Electron beam computed tomography
... who had undergone EBCT scanning at the same time as coronary angiography were contacted after a mean of 6·9 years[35]. It was found that there was a significant relative risk ratio (1·88; P < 0·05) associated with the extent of coronary calcification at baseline and the incidence of future hard card ...
... who had undergone EBCT scanning at the same time as coronary angiography were contacted after a mean of 6·9 years[35]. It was found that there was a significant relative risk ratio (1·88; P < 0·05) associated with the extent of coronary calcification at baseline and the incidence of future hard card ...
article for Myocardial infarction
... myocardial infarction is characterized by the presence of polymorphonuclear leukocytes. If the time interval between the onset of the infarction and death is quite brief, e.g. 6 h, minimal or no polymorphonuclear leukocytes may be seen. The presence of mononuclear cells and fibroblasts, and the abse ...
... myocardial infarction is characterized by the presence of polymorphonuclear leukocytes. If the time interval between the onset of the infarction and death is quite brief, e.g. 6 h, minimal or no polymorphonuclear leukocytes may be seen. The presence of mononuclear cells and fibroblasts, and the abse ...
as a PDF - Lettre de l`UFCV N°58
... of the ESC Scientific and Clinical Initiatives Committee, who helped initiate this joint effort. Experts in the subject under consideration have been selected from all three organizations to examine subject-specific data and write guidelines. The process includes additional representatives from other ...
... of the ESC Scientific and Clinical Initiatives Committee, who helped initiate this joint effort. Experts in the subject under consideration have been selected from all three organizations to examine subject-specific data and write guidelines. The process includes additional representatives from other ...
2.2. The object of the study
... the functional state of the cardiovascular system given different clinical situations (with anxiety and without). Novelty, scientific and practical value of the study The alternation of the cardiovascular system’s functional parameters (except RR interval) during the practice of different relaxation ...
... the functional state of the cardiovascular system given different clinical situations (with anxiety and without). Novelty, scientific and practical value of the study The alternation of the cardiovascular system’s functional parameters (except RR interval) during the practice of different relaxation ...
Attila Borbély, Loek van Heerebeek and Walter J. Paulus 2009, 104:12-14
... Lower cardiomyocyte resting tension following administration of PKG or PKA could result not only from more phosphorylation of titin but also from less actin–myosin interaction of weakly bound crossbridges. An effect of weakly bound crossbridges on resting tension of normal cardiac myofibrils was rul ...
... Lower cardiomyocyte resting tension following administration of PKG or PKA could result not only from more phosphorylation of titin but also from less actin–myosin interaction of weakly bound crossbridges. An effect of weakly bound crossbridges on resting tension of normal cardiac myofibrils was rul ...
Downloaded - VU-dare
... Lower cardiomyocyte resting tension following administration of PKG or PKA could result not only from more phosphorylation of titin but also from less actin–myosin interaction of weakly bound crossbridges. An effect of weakly bound crossbridges on resting tension of normal cardiac myofibrils was rul ...
... Lower cardiomyocyte resting tension following administration of PKG or PKA could result not only from more phosphorylation of titin but also from less actin–myosin interaction of weakly bound crossbridges. An effect of weakly bound crossbridges on resting tension of normal cardiac myofibrils was rul ...
ACC/AHA/ESC 2006 Guidelines for the
... 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854–906. This article has been copublished in the August 15, 2006, issues of Circulation and the Journal of the American College of Cardiology and the August 16, 2006, issue of the European Heart Jour ...
... 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854–906. This article has been copublished in the August 15, 2006, issues of Circulation and the Journal of the American College of Cardiology and the August 16, 2006, issue of the European Heart Jour ...
Smith, Jr, John A. Spertus and Sankey V. Williams Prager, Joseph F
... The writing committee gratefully acknowledges the memory of James T. Dove, MD, who died during the development of this document but contributed immensely to our understanding of stable ischemic heart disease. *Writing committee members are required to recuse themselves from voting on sections to whi ...
... The writing committee gratefully acknowledges the memory of James T. Dove, MD, who died during the development of this document but contributed immensely to our understanding of stable ischemic heart disease. *Writing committee members are required to recuse themselves from voting on sections to whi ...
ACC/AHA 2004 STEMI Guidelines
... 7.1.1. Coronary Care Unit............................................ e82 7.1.1.1. Monitoring and Treatment for Adverse Events.....................................................e83 7.1.2. Stepdown Unit.................................................... e84 7.2. Early, General Measures............ ...
... 7.1.1. Coronary Care Unit............................................ e82 7.1.1.1. Monitoring and Treatment for Adverse Events.....................................................e83 7.1.2. Stepdown Unit.................................................... e84 7.2. Early, General Measures............ ...
ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction
... 7.1.1. Coronary Care Unit...........................................e163 7.1.1.1. Monitoring and Treatment for Adverse Events...................................................e164 7.1.2. Stepdown Unit...................................................e165 7.2. Early, General Measures............... ...
... 7.1.1. Coronary Care Unit...........................................e163 7.1.1.1. Monitoring and Treatment for Adverse Events...................................................e164 7.1.2. Stepdown Unit...................................................e165 7.2. Early, General Measures............... ...
DOI: 10.1161/CIRCULATIONAHA.106.177031 published online Aug
... of Patients With Atrial Fibrillation . . . . . . . . . .000 1. Newly Discovered Atrial Fibrillation. . . . . .000 2. Recurrent Paroxysmal Atrial Fibrillation . . . .000 3. Recurrent Persistent Atrial Fibrillation . . . .000 4. Permanent Atrial Fibrillation . . . . . . . . . . . .000 Appendix I . . . ...
... of Patients With Atrial Fibrillation . . . . . . . . . .000 1. Newly Discovered Atrial Fibrillation. . . . . .000 2. Recurrent Paroxysmal Atrial Fibrillation . . . .000 3. Recurrent Persistent Atrial Fibrillation . . . .000 4. Permanent Atrial Fibrillation . . . . . . . . . . . .000 Appendix I . . . ...
Chapter 19
... Extra heart sounds: fourth heart sound (S4) • Occurs at end of diastole, at presystole, when ventricle resistant to filling • Atria contract and push blood into noncompliant ventricle • This creates vibrations that are heard as S4 • S4 occurs just before S1 ...
... Extra heart sounds: fourth heart sound (S4) • Occurs at end of diastole, at presystole, when ventricle resistant to filling • Atria contract and push blood into noncompliant ventricle • This creates vibrations that are heard as S4 • S4 occurs just before S1 ...
Guidelines - Lettre de l`UFCV N°58
... of Patients With Atrial Fibrillation . . . . . . . . . .738 1. Newly Discovered Atrial Fibrillation. . . . . .738 2. Recurrent Paroxysmal Atrial Fibrillation . . . .738 3. Recurrent Persistent Atrial Fibrillation . . . .739 4. Permanent Atrial Fibrillation . . . . . . . . . . . .739 Appendix I . . . ...
... of Patients With Atrial Fibrillation . . . . . . . . . .738 1. Newly Discovered Atrial Fibrillation. . . . . .738 2. Recurrent Paroxysmal Atrial Fibrillation . . . .738 3. Recurrent Persistent Atrial Fibrillation . . . .739 4. Permanent Atrial Fibrillation . . . . . . . . . . . .739 Appendix I . . . ...
2014 ESC/EACTS Guidelines on myocardial revascularization
... Disclaimer 2014: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity ...
... Disclaimer 2014: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity ...
2014 ESC/EACTS Guidelines on myocardial revascularization
... Disclaimer 2014: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity ...
... Disclaimer 2014: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity ...
2014 ESC/EACTS Guidelines on myocardial
... Disclaimer 2014: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity ...
... Disclaimer 2014: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity ...
Guidelines ESC EACTS 2014 Guidelines on myocardial
... Disclaimer 2014: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity ...
... Disclaimer 2014: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity ...
Crawford Current Cardiology Edition 2
... 2. Dyspnea—A frequent complaint of patients with a variety of cardiac diseases, dyspnea is ordinarily one of four types. The most common is exertional dyspnea, which usually means that the underlying condition is mild because it requires the increased demand of exertion to precipitate symptoms. The ...
... 2. Dyspnea—A frequent complaint of patients with a variety of cardiac diseases, dyspnea is ordinarily one of four types. The most common is exertional dyspnea, which usually means that the underlying condition is mild because it requires the increased demand of exertion to precipitate symptoms. The ...
ACC/AHA/ESC Practice Guidelines
... 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854–906. This article has been copublished in the August 15, 2006, issues of Circulation and the Journal of the American College of Cardiology and the August 16, 2006, issue of the European Heart Jour ...
... 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854–906. This article has been copublished in the August 15, 2006, issues of Circulation and the Journal of the American College of Cardiology and the August 16, 2006, issue of the European Heart Jour ...
Running head: ATRIAL FIBRILLATION
... Medication is not the only option for the treatment of atrial fibrillation. In some patients a conversion to a normal sinus rhythm is warranted so treatments such as cardioversions, ablations, Cox Maze surgery and atrial pacing are preferred. Cardioversions via drugs or electric shock is used to res ...
... Medication is not the only option for the treatment of atrial fibrillation. In some patients a conversion to a normal sinus rhythm is warranted so treatments such as cardioversions, ablations, Cox Maze surgery and atrial pacing are preferred. Cardioversions via drugs or electric shock is used to res ...
The pulmonary hemodynamics and exercise in
... Systolic and/or diastolic dysfunction of the left ventricle are frequently found in the elderly population (28). And as the number one risk factor for COPD, smoking, is also risk factor for left ventricular dysfunction, it is not surprising that the two co-exist (29). However, in the absence of syst ...
... Systolic and/or diastolic dysfunction of the left ventricle are frequently found in the elderly population (28). And as the number one risk factor for COPD, smoking, is also risk factor for left ventricular dysfunction, it is not surprising that the two co-exist (29). However, in the absence of syst ...
Amiodarone Hydrochloride 150 mg/3 mL Name of the
... incompletely and erratically absorbed following oral administration. Absolute bioavailability ranges from 22 - 86% but there is extensive inter-subject variation. First-pass metabolism in the gut wall and/or in the liver may be a factor in determining the availability of the medicine. A HPLC method ...
... incompletely and erratically absorbed following oral administration. Absolute bioavailability ranges from 22 - 86% but there is extensive inter-subject variation. First-pass metabolism in the gut wall and/or in the liver may be a factor in determining the availability of the medicine. A HPLC method ...
Employing vasopressin during cardiopulmonary resuscitation and
... epinephrine. These results are striking, since epinephrine selectively spares the cerebral circulation from vasoconstriction when administered during CPR alone. Administration of endobronchial drugs during CPR may be a simple and rapid alternative, when intubation is performed before intravenous can ...
... epinephrine. These results are striking, since epinephrine selectively spares the cerebral circulation from vasoconstriction when administered during CPR alone. Administration of endobronchial drugs during CPR may be a simple and rapid alternative, when intubation is performed before intravenous can ...
Sleep Society Statement
... respective diagnosis. These can range from nonrestorative sleep and somnolence during the day with an increased risk of accident to cor pulmonale, cardiac arrhythmias, arterial hypertension, atherosclerosis, heart attack, heart failure and stroke. This explains why in many patients it is not the sle ...
... respective diagnosis. These can range from nonrestorative sleep and somnolence during the day with an increased risk of accident to cor pulmonale, cardiac arrhythmias, arterial hypertension, atherosclerosis, heart attack, heart failure and stroke. This explains why in many patients it is not the sle ...
Extracorporeal membrane oxygenation and sepsis
... clot formation or excessively high pressures and should prompt careful review of the circuit. In addition to maximising oxygen delivery, it is important to reduce oxygen consumption. This is facilitated in patients receiving ECMO by controlling body temperature, which is easily achieved by adjusting ...
... clot formation or excessively high pressures and should prompt careful review of the circuit. In addition to maximising oxygen delivery, it is important to reduce oxygen consumption. This is facilitated in patients receiving ECMO by controlling body temperature, which is easily achieved by adjusting ...
Antihypertensive drug
Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure). Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Evidence suggests that reduction of the blood pressure by 5 mmHg can decrease the risk of stroke by 34%, of ischaemic heart disease by 21%, and reduce the likelihood of dementia, heart failure, and mortality from cardiovascular disease. There are many classes of antihypertensives, which lower blood pressure by different means. Among the most important and most widely used drugs are thiazide diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists (ARBs), and beta blockers.Which type of medication to use initially for hypertension has been the subject of several large studies and resulting national guidelines. The fundamental goal of treatment should be the prevention of the important endpoints of hypertension, such as heart attack, stroke and heart failure. Patient age, associated clinical conditions and end-organ damage also play a part in determining dosage and type of medication administered. The several classes of antihypertensives differ in side effect profiles, ability to prevent endpoints, and cost. The choice of more expensive agents, where cheaper ones would be equally effective, may have negative impacts on national healthcare budgets. As of 2009, the best available evidence favors the thiazide diuretics as the first-line treatment of choice for high blood pressure when drugs are necessary. Although clinical evidence shows calcium channel blockers and thiazide-type diuretics are preferred first-line treatments for most people (from both efficacy and cost points of view), an ACE inhibitor is recommended by NICE in the UK for those under 55 years old.